source
- Bankrupt Sangamo sells Fabry gene therapy to PTC and prion program to Lilly for $161MSangamo Therapeutics, currently in Chapter 11 bankruptcy, has agreed to divest its Fabry disease gene therapy and several other platforms to raise cash for the restructuring. PTC Therapeutics emer…
- PTC Therapeutics agrees to pay up to $211 million for Sangamo’s experimental Fabry disease gene therapyPTC Therapeutics announced it will invest up to $211 million to acquire rights to an advanced gene therapy for Fabry disease being developed by Sangamo Therapeutics. The therapy, called ST-920 (is…